GNPX
$1.88-0.04 (-2.08%)
Market ClosedAs of Mar 20, 8:00 PM UTC
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes.
Historical Price
Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$1.88
Potential Upside
5%
Whystock Fair Value$1.97
Price
UndervaluedFair ValueOvervalued
Fundamentals
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.07M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.72
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-2950.81%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.67